Notice of Results

RNS Number : 2890H

SkinBioTherapeutics PLC

02 December 2020

 

2 December 2020

SkinBioTherapeutics plc

Notice of Results

SkinBioTherapeutics plc's (AIM: SBTX or the "Company") financial results for the twelve months to 30 June 2020 will be released on Friday 4 December 2020. The results will be available on the Company's website following release to the London Stock Exchange.

For more information please contact:

SkinBioTherapeutics plc	Tel: [phone]
Stuart Ashman, CEO Doug Quinn, CFO
Cenkos Securities plc (Nominated Adviser & Broker)	Tel: [phone]
Giles Balleny, Max Gould (Corporate Finance) Michael Johnson (Sales)
Instinctif Partners	Tel: [phone]
Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis	[e-mail]

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.

The Company listed on AIM in April 2017 and is based in Manchester, UK.  For more information, visit: www.skinbiotherapeutics.com .

 

END

 

 

NORBBBDDSBGDGGD